Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-20
2010-02-23
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300, C514S252190, C514S260100, C514S274000
Reexamination Certificate
active
07666836
ABSTRACT:
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
REFERENCES:
patent: 5658884 (1997-08-01), Hodgen
patent: 5663145 (1997-09-01), Engel et al.
patent: 0 943 336 (1999-09-01), None
patent: WO 97/19953 (1997-06-01), None
patent: WO 97/27863 (1997-08-01), None
patent: WO 00/55190 (1998-12-01), None
patent: WO98/55470 (1998-12-01), None
H. J. van Geldorp, “Endometriosis,” from the book “In everyday problems in gynecology,” Ed. by I. A. Brosens, Read Healthcare Comm., The Netherlands, 1992, English abstract on p. 6 (an electronic version of the reference is available at http://www.rmj.ru/rmj/13
3/1.htm).
H. P. Zahradnik, et al., “Drug therapy of dysmenorrhea,” Gynakologe, 1988, 21(1): 58-62, abstract.
R.E. Felberbaum, et al., “Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility,” Eur. J. Obstet. Gynecol. Reprod. Biol., 1995, 61(2):151-155, abstract.
Norman, P., “Cetrorelix, Asta Medica AG”, Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs, vol. 2, No. 2, pp. 227-248, XP-00982761, 2000.
Reissman et al.,Human Reproduction, 9:767-769 (1994).
Kettel et al.,Fertility and Sterility, 60:642-646 (1993).
Reissman et al.,Human Reproduction, 10:1974-1981 (1995).
Nachtigall et al., Chapter 41, Danforth's Obstetrics & Gynecology, 1994, pp. 757-759.
Diedrich Klaus
Engel Jurgen
Felberbaum Ricardo
Riethmuller-Winzen Hilde
Wolfgang Kupker
Hui San-ming
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Method for the therapeutic management of endometriosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the therapeutic management of endometriosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the therapeutic management of endometriosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211522